Replies to post #16584 on Cytodyn Inc (CYDY)

[woodenbear]

2Q or 3Q 2018*

[fred198484]

My stance is that you should not buy until the last big dilutive offering has been made. That will certainly happen after the PE data is released and, unfortunately, the stock price will likely be higher at that point than it is now. But while I will have missed the bottom, there should be a whole lot of upside left in the stock over the next several years with nowhere near the risk. As you are well aware, if the primary endpoint data is surprisingly bad, CYDY is in serious trouble as doubts would arise about the mono data as well and it is mono that is the real winner for CYDY.

[tonysd57]

Contrary to dreary old Fred, I see a buy-out in the first quarter of 2018- This is in no way a "several" years holding. Depending on the timeline, we'll have approximately 260 million shares outstanding including all warrants/options at the time of purchase-

I expect the data to be strong and similar to all previous trials, their won't be a big dilutive event if purchased in February as they need approximately $13m-$15m to get their.

Th mono enrollment should be finished, other underlying trials marching forward and the combo data complete - and compelling enough to entice suitors - However, I'm a bit more subdued in my buy-out expectations, I'd say $3.00- $3.50 - $800m to $900m -- JMO - and so I invest accordingly- picked up more today-